What is B. Riley's Forecast for CATX Q3 Earnings?

Key Points

• B. Riley has lowered its Q3 2025 earnings per share (EPS) estimate for Perspective Therapeutics from ($0.30) to ($0.33), maintaining a "Buy" rating and a $12.00 price target on the stock.
• Multiple analysts have rated the stock favorably, with a consensus rating of "Buy" and an average price target of $12.56, despite some recent price cuts by other firms.
• Shares of Perspective Therapeutics have experienced a recent increase of 4.7% and currently trade at $3.54, having a 52-week range of $1.60 to $16.31.

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Stock analysts at B. Riley lowered their Q3 2025 earnings per share estimates for shares of Perspective Therapeutics in a research note issued to investors on Tuesday, September 2nd. B. Riley analyst Y. Zhi now forecasts that the company will post earnings of ($0.33) per share for the quarter, down from their prior forecast of ($0.30). B. Riley has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Perspective Therapeutics' Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.21) EPS.

Several other analysts have also recently weighed in on CATX. Royal Bank Of Canada raised Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and lifted their price objective for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Truist Financial cut their price objective on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Wedbush restated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Monday, June 23rd. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics currently has an average rating of "Buy" and a consensus price target of $12.56.

Perspective Therapeutics Stock Down 0.4%

NYSE:CATX traded down $0.02 during mid-day trading on Friday, reaching $3.36. 324,626 shares of the company's stock traded hands, compared to its average volume of 916,924. Perspective Therapeutics has a 12-month low of $1.60 and a 12-month high of $16.19. The company has a 50 day moving average price of $3.75 and a 200-day moving average price of $2.99.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CATX. ProShare Advisors LLC increased its position in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after acquiring an additional 5,011 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $51,000. Ground Swell Capital LLC bought a new stake in shares of Perspective Therapeutics during the second quarter valued at approximately $56,000. Corton Capital Inc. bought a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $61,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Perspective Therapeutics during the second quarter valued at approximately $61,000. Institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.